Astellas Eschews Foreign Acquisitions As Rivals Go On Buying Spree
This article was originally published in PharmAsia News
Executive Summary
While other Japanese drug makers embarked on an acquisition spree the past year, Astellas Pharma has remained on the sidelines. The company did so even though two of its major drugs that together account for a third of its annual revenues have either lost their patent protection already or soon will do so. Astellas says it is considering licensing agreements as well as acquisitions to build its pipeline in several areas, but one analyst said the firm, despite its $3 billion in cash, still needs to find an acquisition target that works for it. (Click here for more